Interview 26 Jan 2023 Scopio on the future of telehematology Through full-field digital cell morphology, Scopio Labs’ technology can automate the analysis of tens of thousands of cells at a time. This could mean bringing earlier detection and diagnosis of cancers, infections, and other diseases, expediting patients’ access to better care and life-saving treatments. Erez Na’aman, co-founder and CTO of Scopio Labs, tells us about […] January 26, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Dec 2022 Ganymede Bio raises $12.75M for data platform Ganymede Bio, the cloud infrastructure provider purpose-built for the life sciences and manufacturing industries, has announced a $12.75 million series A funding round, led by Caffeinated Capital. This follows a $2.9 million seed round completed earlier this year, bringing the total to more than $15.6 million. Founded in 2022, Ganymede Bio has exceeded $1 million […] December 22, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Startup Scout 15 Sep 2022 Adva Biotechnology is using artificial intelligence to manufacture cell therapies The manufacturing of cell therapies is highly complex, often depending on skilled manual labor. The Israeli startup Adva Biotechnology aims to use automation, optical sensing and artificial intelligence to remove the manual component from the process. Cancer cell therapies such as CAR-T immunotherapies have demonstrated enormous potential for treating forms of blood cancer. Currently available […] September 15, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2022 BigHat Biosciences raises $75M to design safer, more effective antibodies A company developing safer, more effective antibody therapies for patients using machine learning and synthetic biology, today (July 20) announced it has raised $75 million in funding. BigHat Biosciences’ series B funding round was led by Section 32 with participation from new investors Amgen Ventures, Bristol Myers Squibb, Quadrille Capital, Gaingels, GRIDS Capital and others. […] July 20, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
In Depth 19 Apr 2022 How Augmented Reality Strengthens Biotech Manufacturing Biotech and pharma companies are starting to implement augmented reality technologies at their manufacturing facilities, bringing forth a whole new world of possibilities. The Covid-19 pandemic has been a catalyst for embracing new ways of working. Travel restrictions and limited access to facilities have pushed the adoption of technologies that enhance remote work. This is […] April 19, 2022 - 8 minutesmins - By Carlos de Rojas Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jan 2022 Ori Biotech Bags €88M Investment to Automate Cell Therapy Manufacture The UK company Ori Biotech has raised €88M ($100M) in Series B cash to ease the cell therapy manufacturing bottleneck using automation and standardized data collection. The round was 40% oversubscribed and led by the US investment firm Novalis LifeSciences. The Chinese investor Puhua Capital and Chimera Abu Dhabi joined the existing syndicate, which includes […] January 18, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Opinion 10 Nov 2021 Automation Can Solve Diversity Issues in Clinical Trial Recruitment How can we make clinical trial recruitment more reflective of the real world? Technology is coming to the rescue. The quest for diversity in clinical trials goes to the heart of patient care. Why are some demographic groups over-represented in studies when others are more difficult to recruit? Studies that fail to reflect patient demographics […] November 10, 2021 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Interview 22 Feb 2021 How Automation Can Augment Drug Discovery Research Robotics and artificial intelligence are rapidly changing the way we discover drugs. Martin-Immanuel Bittner, CEO and co-founder of Arctoris, discusses the benefits and challenges of introducing automation in drug discovery efforts. The Oxford-based startup Arctoris was established in 2016 with the objective of offering remote access to automated drug discovery. At a time when researchers […] February 22, 2021 - 8 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
In Depth 22 Jul 2020 Artificial Intelligence: A Superpower in the Fight Against Covid-19 The rapid spread of Covid-19 around the world has left drug developers with limited time to identify drug candidates to fight the virus. Amid this crisis, artificial intelligence has proven its value as a tool to make drug discovery faster and cost-effective. Drug discovery is an expensive, long-winded process. Taking a drug from discovery to […] July 22, 2020 - 8 minutesmins - By David Kirk Share WhatsApp Twitter Linkedin Email
News and Trends 8 May 2020 €7M Series A To Democratize Genomics with AI-Driven Cloud Software The UK-based bioinformatics firm Lifebit Biotech has closed a €7M Series A funding round, which will help the startup to accelerate the global market expansion of its AI-driven, cloud-based genomics analysis software. The round was led by the Parisian VC firm Idinvest Partners and also included returning investors Pentech Ventures, Beacon Capital, and Connect Ventures. […] May 8, 2020 - 3 minutesmins - By Laura Cowen Share WhatsApp Twitter Linkedin Email
News and Trends 13 Feb 2020 UK-Swiss Collaboration to Boost Biotech Profits with Automation A partnership between the UK lab automation company Arctoris and Swiss software firm Molecule aims to make it easier to share drug intellectual property in a time of declining returns in pharma. The pharmaceutical industry is struggling with the rising costs of developing new drugs. In fact, the return on investment for drug discovery is […] February 13, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 17 Dec 2018 Series B Boosts British Biotech’s Cell Therapy Automation With €22.6M The UK company Synthace has raised €22.6M to develop its software platform to automate and improve the manufacturing process in gene and cell therapy. The round, led by Hong Kong-based investor Horizons Ventures, will help to fund the development of Synthace’s software designed to automate key protocols in the lab. Furthermore, the funding will help […] December 17, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email